OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders
(a) On June 19, 2018, the Registrant held its Annual General Meeting of Shareholders (the “Meeting”).
(b) The final voting results for the Meeting are as follows:
|
Proposal Number |
Proposal Description |
For |
Against |
Abstain |
Broker Nonvote |
|
|
Election of Ronald A. Andrews, Jr. |
21,143,112 |
118,543 |
|
1,150,229 |
|
|
Election of Mark Klausner |
21,222,731 |
38,924 |
|
1,150,229 |
|
|
Election of James R. Tobin |
21,132,024 |
129,631 |
|
1,150,229 |
|
|
Ratification of Appointment of Auditors for 2018 |
22,404,315 |
8,045 |
|
|
|
|
Re-Appointment of U.K. Statutory Auditors |
22,398,694 |
8,045 |
5,974 |
|
|
|
Authorization to Determine Statutory Auditors’ Remuneration for 2018 |
22,406,179 |
|
6,178 |
|
|
|
Receive U.K. Statutory Accounts and Reports for 2017 |
22,392,428 |
|
19,738 |
|
|
|
Receive and Approve U.K. Statutory Directors’ Annual Report on Remuneration for 2017 |
22,275,224 |
37,136 |
100,353 |
|
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
